Wells Fargo & Company Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its target price cut by investment analysts at Wells Fargo & Company from $145.00 to $136.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target points to a potential upside of 46.66% from the stock’s current price.

RYTM has been the subject of several other reports. Canaccord Genuity Group lifted their price target on shares of Rhythm Pharmaceuticals from $114.00 to $141.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Citizens Jmp increased their price target on Rhythm Pharmaceuticals from $167.00 to $176.00 and gave the stock a “market outperform” rating in a report on Friday. Guggenheim raised their price objective on Rhythm Pharmaceuticals from $140.00 to $143.00 and gave the company a “buy” rating in a research note on Friday. The Goldman Sachs Group increased their target price on Rhythm Pharmaceuticals from $141.00 to $157.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Finally, Zacks Research upgraded shares of Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $133.71.

Rhythm Pharmaceuticals Trading Down 5.4%

Shares of Rhythm Pharmaceuticals stock opened at $92.73 on Friday. The business has a 50-day moving average price of $103.90 and a two-hundred day moving average price of $103.54. Rhythm Pharmaceuticals has a 1-year low of $45.90 and a 1-year high of $122.20. The company has a market cap of $6.19 billion, a P/E ratio of -29.82 and a beta of 2.00.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative return on equity of 378.31% and a negative net margin of 103.57%.The company had revenue of $57.25 million for the quarter, compared to the consensus estimate of $56.16 million. During the same period in the previous year, the business earned ($0.72) EPS. The firm’s revenue was up 36.9% compared to the same quarter last year. Equities research analysts forecast that Rhythm Pharmaceuticals will post -4.32 EPS for the current fiscal year.

Insider Activity

In other Rhythm Pharmaceuticals news, CFO Hunter C. Smith sold 4,385 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $101.26, for a total transaction of $444,025.10. Following the transaction, the chief financial officer owned 110,512 shares of the company’s stock, valued at $11,190,445.12. This trade represents a 3.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Pamela J. Cramer sold 3,350 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $111.00, for a total value of $371,850.00. Following the completion of the transaction, the insider directly owned 20,814 shares of the company’s stock, valued at approximately $2,310,354. This represents a 13.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 25,003 shares of company stock valued at $2,589,015. 6.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of RYTM. EverSource Wealth Advisors LLC increased its stake in shares of Rhythm Pharmaceuticals by 303.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock worth $28,000 after purchasing an additional 200 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Rhythm Pharmaceuticals by 97.2% in the third quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock valued at $29,000 after acquiring an additional 141 shares during the period. SBI Securities Co. Ltd. grew its position in shares of Rhythm Pharmaceuticals by 73.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock valued at $37,000 after purchasing an additional 145 shares in the last quarter. Farther Finance Advisors LLC grew its position in Rhythm Pharmaceuticals by 1,110.3% during the third quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock worth $35,000 after buying an additional 322 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Rhythm Pharmaceuticals by 48.6% during the fourth quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock worth $39,000 after purchasing an additional 118 shares in the last quarter.

Key Headlines Impacting Rhythm Pharmaceuticals

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat estimates: EPS of $-0.73 vs. consensus of $-0.79 and revenue of $57.25M (y/y revenue +36.9%). The beat supports commercial traction for IMCIVREE. Zacks: Rhythm Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Analyst upgrade/target raise: Citizens JMP raised its price target to $176 and kept a “market outperform” rating, signaling strong upside to Street models. Benzinga: Citizens JMP raises PT
• Positive Sentiment: Analyst raise: Guggenheim lifted its target to $143 and maintained a “buy” rating, adding another constructive analyst signal. Benzinga: Guggenheim raises PT
• Positive Sentiment: Near‑term clinical/regulatory catalysts remain: PDUFA goal date for the sNDA in acquired hypothalamic obesity on March 20, plus March topline readouts from Phase 3 programs (EMANATE and a Japanese cohort) that could significantly re‑rate the story. GlobeNewswire: Rhythm Reports Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Analyst trim but still constructive: Wells Fargo cut its target to $136 but kept an “overweight” rating, signaling continued confidence despite a smaller upside. Benzinga: Wells Fargo lowers PT
• Neutral Sentiment: Needham lowered its target to $139 but maintained a “buy”—another sign that sell‑side views remain broadly positive even as models are adjusted. TickerReport: Needham lowers PT
• Negative Sentiment: Large near‑term spending guide: Rhythm told investors it expects $385M–$415M in 2026 non‑GAAP operating expenses as hypothalamic‑obesity (HO) launch preparations accelerate — higher burn that may pressure margins and cash runway in the near term. Seeking Alpha: Rhythm anticipates $385M–$415M in 2026 non‑GAAP operating expenses

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.